Top advances of the year: Leukemia
Sign Up to like & getrecommendations! Published in 2022 at "Cancer"
DOI: 10.1002/cncr.34619
Abstract: In the year 2021, there were three new Food and Drug Administration approvals for all leukemia types: asciminib (Scemblix) for chronic myeloid leukemia, brexucabtagene autoleucel (Tecartus) for relapsed/refractory B‐cell acute lymphocytic leukemia, and asparaginase erwinia… read more here.
Keywords: top advances; leukemia; advances year; brexucabtagene autoleucel ... See more keywords